A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1748-717X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer ; volume:14 ; number:1 ; day:2 ; month:9 ; year:2019 ; pages:1-6 ; date:12.2019
Radiation oncology ; 14, Heft 1 (2.9.2019), 1-6, 12.2019
- Urheber
-
Kainuma, Takuro
Kawakami, Shogo
Tsumura, Hideyasu
Satoh, Takefumi
Tabata, Ken-ichi
Iwamura, Masatsugu
Hayakawa, Kazushige
Ishiyama, Hiromichi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13014-019-1369-y
- URN
-
urn:nbn:de:101:1-2020022022113244575773
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kainuma, Takuro
- Kawakami, Shogo
- Tsumura, Hideyasu
- Satoh, Takefumi
- Tabata, Ken-ichi
- Iwamura, Masatsugu
- Hayakawa, Kazushige
- Ishiyama, Hiromichi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
PK/PD modeling supports the dose-escalation decision in VIKING
Phase I dose-escalation oncology trials with sequential multiple schedules
A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial)
A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study
Dose escalation with stereotactic body radiotherapy for cervical cancer treatment
A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
A dose-escalation ex vivo study on the effects of intracameral benzalkonium chloride in rabbits
Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial
Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
PK/PD modeling supports the dose-escalation decision in VIKING
Phase I dose-escalation oncology trials with sequential multiple schedules
A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial)
A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study
Dose escalation with stereotactic body radiotherapy for cervical cancer treatment
A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
A dose-escalation ex vivo study on the effects of intracameral benzalkonium chloride in rabbits
Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial
Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
PK/PD modeling supports the dose-escalation decision in VIKING
Phase I dose-escalation oncology trials with sequential multiple schedules
A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial)
A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study
Dose escalation with stereotactic body radiotherapy for cervical cancer treatment
A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
A dose-escalation ex vivo study on the effects of intracameral benzalkonium chloride in rabbits
Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial